Cite
HARVARD Citation
Sandborn, W. et al. (n.d.). DOP46 Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial. Journal of Crohn's and colitis. p. S054. [Online].